Boosman, René J. http://orcid.org/0000-0002-6399-2604
de Gooijer, Cornedine J.
Groenland, Stefanie L.
Burgers, Jacobus A.
Baas, Paul
van der Noort, Vincent
Beijnen, Jos H.
Huitema, Alwin D.R.
Steeghs, Neeltje
Article History
Received: 3 January 2022
Accepted: 21 March 2022
First Online: 29 March 2022
Declarations
:
: R.J. Boosman, C.J. de Gooijer, S.L. Groenland, P. Baas, V. van der Noort and A.D.R. Huitema declare they have no conflict of interest to report.<b>J.A. Burgers</b> attended advisory boards for Roche and received grants for the institute from MSD.<b>J.H. Beijnen</b> has received payment for expert testimony for Hoyng Tokh Monegier (paid to their institution), is a part-time employee and (in)direct stockholder of Modra Pharmaceuticals and (jointly) holds a patent on oral taxane formulations, which are clinically developed by Modra Pharmaceuticals. Modra Pharmaceuticals is a small spin-off company of the Netherlands Cancer Institute. All of these conflicts are outside of the submitted work.<b>N. Steeghs</b> provided consultation or attended advisory boards for Boehringer Ingelheim, Ellipses Pharma. N Steeghs received research grants for the institute from AB Science, Abbvie, Actuate Therapeutics, ADCtherapeutics, Amgen, Array, Ascendis Pharma, Astex, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, Celgene, CellCentric, Cresecendo, Cytovation, Deciphera, Eli Lilly, Exelixis, Genentech, Genmab, Gilead, GlaxoSmithKline, Incyte, InteRNA, Janssen/Johnson&Johnson, Kinate, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Novartis, Numab, Pfizer, Pierre Fabre, Regeneron, Roche, Sanofi, Seattle Genetics, Servier, Taiho, Takeda (outside the submitted work).
Free to read: This content has been made available to all.